BioCardia submits revised FDA pre-submission for Helix catheter
The company reported on October 1, 2026 that it filed an updated De Novo pre-submission with FDA's device center for its Helix catheter.
SEC filing
Latest
14 stories
Today
Yesterday
Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world data
Friday, September 25
Novo Nordisk registers Phase 3 trial for denecimig in acquired haemophilia A, plus new Phase 1 study
Wednesday, September 16
Novo Nordisk registers Phase 3 obesity trial in Japan; new CagriSema switch study
Friday, September 11
Novo Nordisk registers two Phase 1 PK trials for zenagamtide and NNC0537-1482
Tuesday, September 1
Novo Nordisk registers Phase 3 zenagamtide trial in T2D and first-in-human study for NNC0705-0002
Monday, August 24
Novo Nordisk registers real-world cardiometabolic study using Turkish EHR data
Friday, August 21
Novo Nordisk posts PIONEER TEENS results; registers three new trials for obesity and injections
Friday, August 14
Novo Nordisk posts results for two semaglutide trials, opens new NNC0487-0111 study
Monday, August 10
Veru's Phase 2b PLATEAU trial fully enrolled with 239 obesity patients
Veru said the enobosarm-semaglutide combination trial exceeded its enrollment target as the company reported fiscal Q3 2026 results and a pending key patent allowance.
SEC filing